The Turkish Journal of Pediatrics 2019 , Vol 61 , Num 2
Hemophagocytic lymphohistiocytosis associated with oxcarbazepine
Serkan Kırık 1 ,Hatice Güneş 2 ,Sadık Yurttutan 2 ,Nafiz Sarışık 2 ,Can Acıpayam 2 ,Yasemin Kırık 3
1 Departments of Pediatric Neurology, Kahramanmaras Sutcu Imam University, Faculty of Medicine, Kahramanmaras, Turkey
2 Departments of Pediatrics, Kahramanmaras Sutcu Imam University, Faculty of Medicine, Kahramanmaras, Turkey
3 Department of Infectious Diseases and Clinical Microbiology, Necip Fazıl State Hospital, Kahramanmaras, Turkey
DOI : 10.24953/turkjped.2019.02.025 Kırık S, Güneş H, Yurttutan S, Sarışık N, Acıpayam C, Kırık Y. Hemophagocytic lymphohistiocytosis associated with oxcarbazepine. Turk J Pediatr 2019; 61: 297-300.

Hemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening multisystem disorder. Reports of the disorder as a side effect of drugs are extremely rare. We report the case of a 3-year-old boy with a history of epileptic seizures in which oxcarbazepine was added to treatment for the last 35 days and dose had been increased. For 10 days he had a fever, hepatosplenomegaly, rash, edema and other systemic symptoms. He was diagnosed with HLH after bone marrow examination. Oxcarbazepine treatment was terminated after the intravenous immunoglobulin treatment. The next day, clinical and laboratory results had improved. This is the first HLH report of an association with oxcarbazepine. Bone marrow aspiration may be indicated to confirm the diagnosis when facing a patient with systemic symptoms after newly added antiepileptic drug treatment. Keywords : epilepsy, hemophagocytic lymphohistiocytosis, oxcarbazepine

Copyright © 2016